1. Home
  2. IVA vs HBIO Comparison

IVA vs HBIO Comparison

Compare IVA & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • HBIO
  • Stock Information
  • Founded
  • IVA 2011
  • HBIO 1901
  • Country
  • IVA France
  • HBIO United States
  • Employees
  • IVA N/A
  • HBIO N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • HBIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • IVA Health Care
  • HBIO Industrials
  • Exchange
  • IVA Nasdaq
  • HBIO Nasdaq
  • Market Cap
  • IVA 359.6M
  • HBIO 19.6M
  • IPO Year
  • IVA 2020
  • HBIO 2000
  • Fundamental
  • Price
  • IVA $3.48
  • HBIO $0.43
  • Analyst Decision
  • IVA Strong Buy
  • HBIO Buy
  • Analyst Count
  • IVA 4
  • HBIO 2
  • Target Price
  • IVA $10.50
  • HBIO $3.00
  • AVG Volume (30 Days)
  • IVA 15.6K
  • HBIO 1.1M
  • Earning Date
  • IVA 03-26-2025
  • HBIO 08-07-2025
  • Dividend Yield
  • IVA N/A
  • HBIO N/A
  • EPS Growth
  • IVA N/A
  • HBIO N/A
  • EPS
  • IVA N/A
  • HBIO N/A
  • Revenue
  • IVA $14,591,573.00
  • HBIO $91,397,000.00
  • Revenue This Year
  • IVA $15.38
  • HBIO N/A
  • Revenue Next Year
  • IVA $24.22
  • HBIO $9.75
  • P/E Ratio
  • IVA N/A
  • HBIO N/A
  • Revenue Growth
  • IVA N/A
  • HBIO N/A
  • 52 Week Low
  • IVA $1.53
  • HBIO $0.28
  • 52 Week High
  • IVA $4.05
  • HBIO $3.60
  • Technical
  • Relative Strength Index (RSI)
  • IVA 52.61
  • HBIO 45.04
  • Support Level
  • IVA $3.13
  • HBIO $0.42
  • Resistance Level
  • IVA $3.48
  • HBIO $0.48
  • Average True Range (ATR)
  • IVA 0.24
  • HBIO 0.04
  • MACD
  • IVA 0.03
  • HBIO -0.01
  • Stochastic Oscillator
  • IVA 51.90
  • HBIO 8.15

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

Share on Social Networks: